AI summary · may contain errors
In fee-for-service Medicare patients with incident cancer (2014–2020), oncologists’ guideline-preferred drug payments were linked to higher receipt of preferred treatment (RR=1.06).
Moving in JNCI: Journal of the National Cancer Institute, Journal of Clinical Oncology, JAMA Oncology, Journal of the American College of Cardiology, The Medical Journal of Australia, Annals of Internal Medicine, Annals of Oncology and BMJ.
Rebuilt
Nothing in this topic has moved yet this week.
Newest first · last 60 days
AI summary · may contain errors
In fee-for-service Medicare patients with incident cancer (2014–2020), oncologists’ guideline-preferred drug payments were linked to higher receipt of preferred treatment (RR=1.06).
AI summary · may contain errors
A structured collaboration framework for academia–medical industry partnerships defines six integrity principles—transparency, independence, accountability, equity, sustainability, and patient-centred benefit—to strengthen governance.
AI summary · may contain errors
Commercial determinants of health capture how corporate products and practices harm health and environments, with mega-corporations exerting broad influence through multiple channels.
AI summary · may contain errors
Between 2013–2022 in Australia, 45 pharmaceutical companies disclosed $95.7 million to 390 patient groups, with 13 groups receiving 47.9% of payments.
AI summary · may contain errors
FDA decisions on oncology drug trials for refractory melanoma in the US are discussed as potentially harming the regulatory environment for future cancer-drug development.
AI summary · may contain errors
US federally sponsored cancer clinical trials (n=11,681; 18.1%) are less likely than industry trials (n=9,569; 81.9%) to be single-agent cancer treatment studies (48.6% vs 77.4%; OR 0.28).
Journals this month
Topics moving, week to 17 Nov 2026
By field